These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33938078)

  • 21. Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device.
    Kaneko H; Neuss M; Weissenborn J; Butter C
    Heart Vessels; 2017 Sep; 32(9):1137-1143. PubMed ID: 28477098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of Left Atrial Appendage Occlusion in Left Atrial Appendage Thrombus: A Systematic Review.
    Sharma SP; Cheng J; Turagam MK; Gopinathannair R; Horton R; Lam YY; Tarantini G; D'Amico G; Freixa Rofastes X; Lange M; Natale A; Lakkireddy DR
    JACC Clin Electrophysiol; 2020 Apr; 6(4):414-424. PubMed ID: 32327075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
    Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
    J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.
    Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Foley D; Sievert H; Mazzone P; De Potter T; Vireca E; Stein K; Bergmann MW;
    Heart Rhythm; 2017 Sep; 14(9):1302-1308. PubMed ID: 28577840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review.
    Baman JR; Mansour M; Heist EK; Huang DT; Biton Y
    Heart Fail Rev; 2018 Mar; 23(2):191-208. PubMed ID: 29453694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebral protection in left atrial appendage closure in the presence of appendage thrombosis.
    Boccuzzi GG; Montabone A; D'Ascenzo F; Colombo F; Ugo F; Muraglia S; De Backer O; Nombela-Franco L; Meincke F; Mazzone P
    Catheter Cardiovasc Interv; 2021 Feb; 97(3):511-515. PubMed ID: 32808741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ALSTER-FLX Registry: 3-Month outcomes after left atrial appendage occlusion using a next-generation device, a matched-pair analysis to EWOLUTION.
    Paitazoglou C; Meincke F; Bergmann MW; Eitel I; Fink T; Vireca E; Wohlmuth P; Veliqi E; Willems S; Markiewicz A; Grygier M
    Heart Rhythm; 2022 Jun; 19(6):917-926. PubMed ID: 35181483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of thrombus formation after electrical isolation of the left atrial appendage in patients with atrial fibrillation.
    Fink T; Ouyang F; Heeger CH; Sciacca V; Reissmann B; Keelani A; Schütte C; Wohlmuth P; Maurer T; Rottner L; Eitel C; Eitel I; Rillig A; Metzner A; Kuck KH; Tilz RR; Vogler J
    Europace; 2020 Sep; 22(9):1358-1366. PubMed ID: 32743641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation.
    Stone D; Byrne T; Pershad A
    Catheter Cardiovasc Interv; 2015 Jul; 86(1):121-7. PubMed ID: 23765504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Watchman in ascending aorta for systemic protection (WAASP): Novel use of Watchman in ascending aorta for embolic protection-first in man.
    Yadav PK; Wang DD; Eng MH; O'Neill WW
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):433-436. PubMed ID: 28471099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Closure of Left Atrial Appendage With Persistent Distal Thrombus Using an Amplatzer Amulet Occluder.
    Lange M; Bültel H; Weglage H; Löffeld P; Wichter T
    J Invasive Cardiol; 2016 Sep; 28(9):E75-6. PubMed ID: 27591691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients.
    Kubo S; Mizutani Y; Meemook K; Nakajima Y; Hussaini A; Kar S
    JACC Clin Electrophysiol; 2017 Dec; 3(12):1380-1386. PubMed ID: 29759668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Efficacy and Safety of the WATCHMAN Device in LAA Occlusion in Patients with Non-Valvular Atrial Fibrillation Contraindicated to Oral Anticoagulation: A Focused Review.
    Majule DN; Jing C; Rutahoile WM; Shonyela FS
    Ann Thorac Cardiovasc Surg; 2018 Dec; 24(6):271-278. PubMed ID: 29962388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience.
    Chun KR; Bordignon S; Urban V; Perrotta L; Dugo D; Fürnkranz A; Nowak B; Schmidt B
    Heart Rhythm; 2013 Dec; 10(12):1792-9. PubMed ID: 23973952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation.
    Onalan O; Crystal E
    Stroke; 2007 Feb; 38(2 Suppl):624-30. PubMed ID: 17261703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation.
    Sick PB; Schuler G; Hauptmann KE; Grube E; Yakubov S; Turi ZG; Mishkel G; Almany S; Holmes DR
    J Am Coll Cardiol; 2007 Apr; 49(13):1490-5. PubMed ID: 17397680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Left atrial appendage closure: First in man with the 4th generation WATCHMAN device.
    Ledwoch J; Franke J; Gonzaga M; Bertog S; Braut A; Hofmann I; Vaskelyte L; Gafoor S; Reddy V; Sievert H
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):787-94. PubMed ID: 26354821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
    Ramlawi B; Abu Saleh WK; Edgerton J
    Methodist Debakey Cardiovasc J; 2015; 11(2):100-3. PubMed ID: 26306127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).
    Reddy VY; Möbius-Winkler S; Miller MA; Neuzil P; Schuler G; Wiebe J; Sick P; Sievert H
    J Am Coll Cardiol; 2013 Jun; 61(25):2551-6. PubMed ID: 23583249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.